223 related articles for article (PubMed ID: 34428613)
1. Mismatch repair proteins PMS2 and MLH1 can further refine molecular stratification of IDH-mutant lower grade astrocytomas.
Yang RR; Li KK; Zhang ZY; Chan AK; Wang WW; Chan DT; Li WC; Liu XZ; Li FC; Chen H; Ng HK; Mao Y; Shi ZF
Clin Neurol Neurosurg; 2021 Sep; 208():106882. PubMed ID: 34428613
[TBL] [Abstract][Full Text] [Related]
2. IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations.
Yang RR; Shi ZF; Zhang ZY; Chan AK; Aibaidula A; Wang WW; Kwan JSH; Poon WS; Chen H; Li WC; Chung NY; Punchhi G; Chu WC; Chan IS; Liu XZ; Mao Y; Li KK; Ng HK
Brain Pathol; 2020 May; 30(3):541-553. PubMed ID: 31733156
[TBL] [Abstract][Full Text] [Related]
3. Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis.
Suwala AK; Stichel D; Schrimpf D; Kloor M; Wefers AK; Reinhardt A; Maas SLN; Kratz CP; Schweizer L; Hasselblatt M; Snuderl M; Abedalthagafi MSJ; Abdullaev Z; Monoranu CM; Bergmann M; Pekrun A; Freyschlag C; Aronica E; Kramm CM; Hinz F; Sievers P; Korshunov A; Kool M; Pfister SM; Sturm D; Jones DTW; Wick W; Unterberg A; Hartmann C; Dodgshun A; Tabori U; Wesseling P; Sahm F; von Deimling A; Reuss DE
Acta Neuropathol; 2021 Jan; 141(1):85-100. PubMed ID: 33216206
[TBL] [Abstract][Full Text] [Related]
4. Molecular landscape of IDH-mutant primary astrocytoma Grade IV/glioblastomas.
Wong QH; Li KK; Wang WW; Malta TM; Noushmehr H; Grabovska Y; Jones C; Chan AK; Kwan JS; Huang QJ; Wong GC; Li WC; Liu XZ; Chen H; Chan DT; Mao Y; Zhang ZY; Shi ZF; Ng HK
Mod Pathol; 2021 Jul; 34(7):1245-1260. PubMed ID: 33692446
[TBL] [Abstract][Full Text] [Related]
5. [Correlation between mismatch-repair protein expression and clinicopathologic features in 658 colorectal cancers].
Hu XR; Xu C; Kang Y; Wang T; Zhang Y; Yang XH
Zhonghua Bing Li Xue Za Zhi; 2018 Nov; 47(11):827-833. PubMed ID: 30423605
[No Abstract] [Full Text] [Related]
6. Utility of methylthioadenosine phosphorylase immunohistochemical deficiency as a surrogate for CDKN2A homozygous deletion in the assessment of adult-type infiltrating astrocytoma.
Satomi K; Ohno M; Matsushita Y; Takahashi M; Miyakita Y; Narita Y; Ichimura K; Yoshida A
Mod Pathol; 2021 Apr; 34(4):688-700. PubMed ID: 33077924
[TBL] [Abstract][Full Text] [Related]
7. Homozygous deletion of CDKN2A by fluorescence in situ hybridization is prognostic in grade 4, but not grade 2 or 3, IDH-mutant astrocytomas.
Marker DF; Pearce TM
Acta Neuropathol Commun; 2020 Oct; 8(1):169. PubMed ID: 33081848
[TBL] [Abstract][Full Text] [Related]
8. Correlating MRI features with additional genetic markers and patient survival in histological grade 2-3 IDH-mutant astrocytomas.
Lasocki A; Buckland ME; Molinaro T; Xie J; Whittle JR; Wei H; Gaillard F
Neuroradiology; 2023 Aug; 65(8):1215-1223. PubMed ID: 37316586
[TBL] [Abstract][Full Text] [Related]
9. PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status.
Roodakker KR; Elsir T; Edqvist PD; Hägerstrand D; Carlson J; Lysiak M; Henriksson R; Pontén F; Rosell J; Söderkvist P; Stupp R; Tchougounova E; Nistér M; Malmström A; Smits A
Oncotarget; 2016 Nov; 7(45):72431-72442. PubMed ID: 27626492
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of DNA mismatch repair enzyme immunohistochemistry as a screening test for hypermutated gliomas.
McCord M; Steffens A; Javier R; Kam KL; McCortney K; Horbinski C
Acta Neuropathol Commun; 2020 Feb; 8(1):15. PubMed ID: 32051040
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinoma and Tumor-associated Immune Cells: Differences Between MLH1 Methylated and Nonmethylated Subgroups.
Kir G; Olgun ZC; Soylemez T; Aydin A; Demircan B; Kaya IA; McCluggage WG
Int J Gynecol Pathol; 2021 Nov; 40(6):575-586. PubMed ID: 33332859
[TBL] [Abstract][Full Text] [Related]
12. Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis.
Richardson TE; Snuderl M; Serrano J; Karajannis MA; Heguy A; Oliver D; Raisanen JM; Maher EA; Pan E; Barnett S; Cai C; Habib AA; Bachoo RM; Hatanpaa KJ
J Neurooncol; 2017 May; 133(1):183-192. PubMed ID: 28421459
[TBL] [Abstract][Full Text] [Related]
13. [Expression and clinical significance of MMR protein and MLH1 promoter methylation testing in endometrial cancer].
Jin W; Wang LQ; Liu Y; Liu AJ
Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):823-830. PubMed ID: 30585020
[No Abstract] [Full Text] [Related]
14. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas.
Shirahata M; Ono T; Stichel D; Schrimpf D; Reuss DE; Sahm F; Koelsche C; Wefers A; Reinhardt A; Huang K; Sievers P; Shimizu H; Nanjo H; Kobayashi Y; Miyake Y; Suzuki T; Adachi JI; Mishima K; Sasaki A; Nishikawa R; Bewerunge-Hudler M; Ryzhova M; Absalyamova O; Golanov A; Sinn P; Platten M; Jungk C; Winkler F; Wick A; Hänggi D; Unterberg A; Pfister SM; Jones DTW; van den Bent M; Hegi M; French P; Baumert BG; Stupp R; Gorlia T; Weller M; Capper D; Korshunov A; Herold-Mende C; Wick W; Louis DN; von Deimling A
Acta Neuropathol; 2018 Jul; 136(1):153-166. PubMed ID: 29687258
[TBL] [Abstract][Full Text] [Related]
15. Lessons learnt from implementation of a Lynch syndrome screening program for patients with gynaecological malignancy.
Najdawi F; Crook A; Maidens J; McEvoy C; Fellowes A; Pickett J; Ho M; Nevell D; McIlroy K; Sheen A; Sioson L; Ahadi M; Turchini J; Clarkson A; Hogg R; Valmadre S; Gard G; Dooley SJ; Scott RJ; Fox SB; Field M; Gill AJ
Pathology; 2017 Aug; 49(5):457-464. PubMed ID: 28669579
[TBL] [Abstract][Full Text] [Related]
16. CDKN2A mutations have equivalent prognostic significance to homozygous deletion in IDH-mutant astrocytoma.
Yokoda RT; Cobb WS; Yong RL; Crary JF; Viapiano MS; Walker JM; Umphlett M; Tsankova NM; Richardson TE
J Neuropathol Exp Neurol; 2023 Sep; 82(10):845-852. PubMed ID: 37550258
[TBL] [Abstract][Full Text] [Related]
17. Lynch Syndrome in Thai Endometrial Cancer Patients.
Manchana T; Ariyasriwatana C; Triratanachat S; Phowthongkum P
Asian Pac J Cancer Prev; 2021 May; 22(5):1477-1483. PubMed ID: 34048176
[TBL] [Abstract][Full Text] [Related]
18. Mismatch repair-deficient glioma with spatially distinct IDH-mutant and IDH-wild type components arising in the setting of Lynch syndrome.
Tan H; Nerison C; Stateler C; Bowden SG; Raslan AM; Ambady P; Barajas RF; Wood MD
Cold Spring Harb Mol Case Stud; 2023 Apr; 9(2):. PubMed ID: 37076313
[TBL] [Abstract][Full Text] [Related]
19. Detection of DNA Mismatch Repair Protein Abnormalities in Sudanese Colorectal Cancer Patients Using Immunohistochemical Methods.
Zakout YM; Lanza G
J Gastrointest Cancer; 2019 Sep; 50(3):530-536. PubMed ID: 29850986
[TBL] [Abstract][Full Text] [Related]
20. [Methylthioadenosine phosphorylase and p16 as surrogate diagnostic markers for CDKN2A homozygous deletion in brain tumors].
Wang SN; Wang W; Zhang XW; Zhang YQ; Xiong YL; Liu L; Teng LH
Zhonghua Bing Li Xue Za Zhi; 2024 May; 53(5):439-445. PubMed ID: 38678323
[No Abstract] [Full Text] [Related]
[Next] [New Search]